Suguna, Head of Business Development at Dewpoint Therapeutics, spearheads the rapid advancement of our early-stage therapeutic pipeline and optimizes the value of Dewpoint's pioneering Condensate biology and AI platform. Suguna achieves this by closely collaborating with the Corporate Development and R&D leadership teams to craft and execute strategic business development initiatives for our technology platform and programs. As a scientist and strategist, she has 20 years of experience in drug discovery, business development and the creation of new ventures to translate breakthrough science into novel therapeutics. This included sourcing, developing, structuring and negotiating business and financial terms for in-licensing and out-licensing transactions. Most recently, Suguna was Sr. Director at the Global Cardiovascular Innovation Center (GCIC) and the NIH Center for Accelerated Innovations at the Cleveland Clinic (NCAI-CC), responsible for the search and evaluation of early-stage therapeutic assets to accelerate drug discovery and development and also supporting preclinical studies. She also led the strategy and operations of a Cleveland Clinic start-up to advance a small molecule for cardiometabolic diseases. Prior to Cleveland Clinic, Suguna led the office of technology commercialization at Kent State University, overseeing all aspects of innovation management. Suguna started her career at United Therapeutics as a drug discovery scientist in the medicinal chemistry team and spent a decade at Pharmasset Inc. working on the discovery and development of antiviral drugs. She was a significant contributor to numerous clinical candidates from H2L to IND enabling studies including the marketed drug Sovaldi®, a cure for HCV. Suguna holds a PhD in Chemistry from the University of Hyderabad, India, and an MBA from New York University. She is a co-author on 30-peer reviewed publications and a co-inventor on 14 issued patents.